https://scholars.lib.ntu.edu.tw/handle/123456789/633535
標題: | Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2 | 作者: | Toi, Masakazu CHIUN-SHENG HUANG Im, Young-Hyuck Sohn, Joohyuk Zhang, Wei Sakaguchi, Sachi Haddad, Nadine van Hal, Gertjan Sledge, George W |
關鍵字: | East Asia; abemaciclib; breast cancer; cyclin-dependent kinase inhibitor; metastatic | 公開日期: | 一月-2023 | 卷: | 114 | 期: | 1 | 來源出版物: | Cancer science | 摘要: | MONARCH 2 is a global, randomized, double-blind, phase 3 study of abemaciclib/placebo + fulvestrant in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative advanced breast cancer. The East Asian population comprised 212 (31.7%) of the 669 intent-to-treat population in the MONARCH 2 trial. Consistent with the primary analysis, this subpopulation analysis of East Asian patients indicated progression-free survival benefit in the abemaciclib arm. The median overall survival was not reached in the abemaciclib arm and was 48.9 months in the placebo arm (hazard ratio 0.80; 95% confidence interval 0.52-1.24; p = 0.377). In addition, other efficacy endpoints, including time to chemotherapy, chemotherapy free survival, and time to second disease progression, indicated benefit in the abemaciclib arm. This analysis found no new safety concerns with longer follow-up. These findings support the positive benefit-risk balance of the MONARCH 2 regimen in East Asian patients with hormone receptor positive, human epidermal growth factor receptor 2-negative advanced breast cancer. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/633535 | ISSN: | 13479032 | DOI: | 10.1111/cas.15600 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。